Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label romiplostim in thrombocytopenic pediatric ITP
2011-005019-96Phase 3Completed
- Sponsor
- Amgen
- Start
- Aug 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of romiplostim in immune thrombocytopenia (ITP), thrombocytopenic purpura, sponsored by Amgen. Started Aug 2014; status: completed.
02
Drugs
romiplostim
03
Conditions
immune thrombocytopenia (ITP)thrombocytopenic purpura
Beyond the preview
Go deeper on 2011-005019-96.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005019-96.